Xavier Llor MD, PhDAssociate Professor; Medical Director, Colorectal Cancer Prevention Program; Co-Director of Cancer Genetics and Prevention Program, Yale University School of Medicine, New Haven, Connecticut
Dr. Xavier Llor obtained his MD degree at the Autonomous University of Barcelona and his PhD in molecular biology at the University of Barcelona. He completed his Internal Medicine Residency at the University of Chicago-Lutheran General Hospital Program and his GI fellowship at the University of Illinois at Chicago. In 2014, Dr. Llor joined Yale University to become co-Director of the Cancer Genetics and Prevention Program at Yale’s Cancer Center, and Medical Director of the Colorectal Cancer Prevention Program. In January 2020 he was been appointed Associate Director for Cancer Screening, Community Engagement and Health Equity at Yale’s Cancer Center.
A clinically active gastroenterologist, Dr. Llor’s research and clinical interests relate to colorectal cancer with an emphasis on genetics and disparities. He spearheaded and carried out three large prospective cohorts of colorectal cancer patients and controls. The first two, Epicolon I and II, were nationwide population-based studies in Spain that have produced over 50 peer-reviewed publications mostly addressing genetic factors implicated in CRC development. The most recent cohort, the Chicago Colorectal Cancer Consortium, was designed to address the influence of genetic and environmental factors on colorectal cancer disparities and has already resulted in a number of manuscripts, some still in preparation. Some important contributions from Dr. Llor’s lab include the description of the best diagnostic approaches to Lynch syndrome diagnosis; clinical and molecular characterization of mismatch repair proficient hereditary non-polyposis colorectal cancer (type X); identification of distinct clinical and molecular features of colorectal cancers in young African Americans.
Dr. Llor has been involved in national scientific organizations for years. He is currently a member of the Steering Committee of the National Colorectal Cancer Roundtable, where he represents the American Gastroenterological Association (AGA), and member of the National Comprehensive Cancer Network guidelines committee on High risk/Inherited colorectal cancer and Colorectal Cancer Screening.
Recent Contributions to PracticeUpdate:
- Histology, Size, and Number of Advanced Polyps Are Associated With Guideline-Discordant Surveillance Recommendations
- Racial and Ethnic Disparities in Germline Genetic Testing of Patients With Young-Onset Colorectal Cancer
- Colonoscopy and Reduction of Colorectal Cancer Risk by Molecular Tumor Subtypes
- Clinical Grade Detection of Microsatellite Instability in Colorectal Tumors by Deep Learning
- Oral Antibiotic Use and Risk of Colorectal Cancer in the UK
- Prevalence of and Risk Factors for Colorectal Neoplasia in Asymptomatic Young Adults
- Genetic Risk Score Is Associated With Prevalence of Advanced Neoplasms in a CRC Screening Population
- Germline Mutations in BRF1 Increase Risk of Hereditary Colorectal Cancer
- Lynch Syndrome Cancer Risk and Survival by Genotype
- Interval Colorectal Cancer Incidence Among Individuals Undergoing Multiple Rounds of Fecal Immunochemical Testing